ID   A549-A2-ESO
AC   CVCL_A0WA
SY   A549-NY-ESO-1-A2-CBG
DR   cancercelllines; CVCL_A0WA
DR   Wikidata; Q108819812
RX   PubMed=33537176;
CC   Population: Caucasian.
CC   Characteristics: Transduced with both a CBG-T2A-GFP construct and a NY-ESO-1-T2A-HLA-A2 construct.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 24198; CTAG1A.
CC   Transfected with: HGNC; 4931; HLA-A (allele A*2).
CC   Transfected with: CBG, click beetle green luciferase.
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A0VZ ! A549-CBG
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 6
//
RX   PubMed=33537176; DOI=10.1080/2162402X.2021.1873607;
RA   Martinez M., Kim S., St Jean N., O'Brien S., Lian L.-R., Sun J.,
RA   Verona R.I., Moon E.;
RT   "Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade
RT   augments human T cell adoptive cell transfer.";
RL   OncoImmunology 10:e1873607.1-e1873607.16(2021).
//